Placebo + Cariprazine
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Schizophrenia
Conditions
Schizophrenia
Trial Timeline
Sep 27, 2011 → Sep 3, 2014
NCT ID
NCT01412060About Placebo + Cariprazine
Placebo + Cariprazine is a phase 3 stage product being developed by Richter Gedeon for Schizophrenia. The current trial status is completed. This product is registered under clinical trial identifier NCT01412060. Target conditions include Schizophrenia.
What happened to similar drugs?
20 of 20 similar drugs in Schizophrenia were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01469377 | Phase 2 | Completed |
| NCT01412060 | Phase 3 | Completed |
| NCT01396447 | Phase 2 | Completed |
Competing Products
20 competing products in Schizophrenia